Rhovica Secures €2.5M to Revolutionize Emergency Brain Surgery with SoNav System
August 27, 2025, 3:32 pm
Rhovica Neuroimaging secured €2.5M to advance SoNav, a bedside navigation system for critical neurosurgical procedures. This innovative technology addresses the trade-off between speed and accuracy in emergency brain pressure relief, offering real-time guidance and continuous monitoring. It promises enhanced patient outcomes, reduced costs, and fewer CT scans. Led by M2care, this funding propels Rhovica into a growing neurosurgical device market, poised to transform urgent brain care. The company’s neurosurgeon founders bring deep clinical insight to this vital medical advancement. SoNav targets a significant unmet need, offering a swift, precise solution where every second counts.
Bern-based MedTech innovator Rhovica Neuroimaging has completed a significant financing round. The startup secured €2.5 million. This capital infusion accelerates development of SoNav, their groundbreaking bedside navigation system. SoNav targets emergency neurosurgery. It aims to dramatically improve critical procedures.
Rhovica Neuroimaging emerged in 2023. Neurosurgeons Martin Hlavica and Thomas Rhomberg co-founded the company. Their mission is clear: enhance emergency treatment. They focus on patients with life-threatening increased brain pressure. Such conditions demand immediate, precise intervention.
Elevated intracranial pressure poses immense danger. It often follows severe trauma or intracranial bleeding. A common life-saving procedure involves external ventricular drain (EVD) placement. This drain relieves pressure. It is a critical, time-sensitive intervention.
Current EVD placement methods present a critical dilemma. Surgeons often perform the procedure freehand at the bedside. This approach is fast. However, it lacks precision. Alternatively, operating room navigation systems offer accuracy. Yet, they introduce significant delays. Urgent care suffers from this trade-off. Patient outcomes can worsen.
Rhovica's SoNav system directly tackles this challenge. It integrates advanced sensors. These provide real-time visualization. Guided catheter insertion occurs directly at the patient's bedside. SoNav eliminates the speed versus accuracy compromise. It ensures both swiftness and precision. This medical device marks a significant leap forward.
Beyond initial placement, SoNav offers continuous monitoring. It tracks brain ventricles. This feature reduces the need for repeated CT scans. Fewer scans mean less radiation exposure. Patient safety improves immediately. Outcomes are enhanced. Healthcare costs also see a notable reduction. The technology streamlines care pathways.
The €2.5 million financing round saw strong investor participation. M2care led the round. Swiss investment firms Kickfund and Valuemaker also joined. Several business angels contributed. These investors bring vital MedTech expertise and extensive networks. Their support is crucial for Rhovica's next development phase.
M2care is a European venture studio. Mérieux Développement and CEA Investissement created it. M2care specializes in healthtech. Its strategy involves combining investment capacity with hands-on expertise. This approach de-risks early-stage healthtech ventures. It prepares them for Series A readiness. M2care recognized Rhovica's strong potential.
Rhovica embodies M2care's investment philosophy. The startup addresses a clear clinical need. Its team is robust. The technology holds transformative power for emergency neurosurgery. M2care expressed pride in actively supporting Rhovica's journey. Their involvement is a strategic endorsement.
The neurosurgical device market shows significant growth potential. Rhovica positions itself strategically within this expanding environment. Industry projections indicate substantial expansion. Growth rates are expected between 4.5% and 14.2% in the coming years. SoNav is poised to capture a key segment.
Rhovica further strengthened its leadership. Carsten Laue joined its Board of Directors. Laue serves as Managing Director at M2care. His expertise is invaluable. He specializes in MedTech strategy and company building. Laue's guidance will accelerate SoNav's clinical adoption. His appointment signals a commitment to rapid progress.
Laue's decision to join the board reflects deep confidence. He aims to actively support Rhovica. His focus is translating a critical clinical need into a viable MedTech solution. SoNav's origin in emergency neurosurgical care is a key factor. The founders' complementary expertise further strengthens the project. This aligns perfectly with M2care's acceleration model.
The company's approach addresses a critical gap. Speed in emergency neurosurgery is paramount. Accuracy is non-negotiable. SoNav delivers both. It offers a new standard of care. Patients facing life-threatening brain conditions stand to benefit profoundly. This innovation can save lives and improve recovery.
Rhovica's success is a testament to focused innovation. The company identified a glaring problem. It engineered a sophisticated, yet practical, solution. The financial backing validates its vision. The strategic appointments strengthen its execution. SoNav promises a brighter future for emergency brain care globally.
The system's real-time capabilities are revolutionary. Surgeons gain unprecedented control. Procedural precision increases. Clinical outcomes improve significantly. The reduction in follow-up imaging lessens patient burden. It also optimizes hospital resources. Rhovica is not just developing a device; it is shaping a new paradigm for urgent medical intervention.
Bern-based MedTech innovator Rhovica Neuroimaging has completed a significant financing round. The startup secured €2.5 million. This capital infusion accelerates development of SoNav, their groundbreaking bedside navigation system. SoNav targets emergency neurosurgery. It aims to dramatically improve critical procedures.
Rhovica Neuroimaging emerged in 2023. Neurosurgeons Martin Hlavica and Thomas Rhomberg co-founded the company. Their mission is clear: enhance emergency treatment. They focus on patients with life-threatening increased brain pressure. Such conditions demand immediate, precise intervention.
Elevated intracranial pressure poses immense danger. It often follows severe trauma or intracranial bleeding. A common life-saving procedure involves external ventricular drain (EVD) placement. This drain relieves pressure. It is a critical, time-sensitive intervention.
Current EVD placement methods present a critical dilemma. Surgeons often perform the procedure freehand at the bedside. This approach is fast. However, it lacks precision. Alternatively, operating room navigation systems offer accuracy. Yet, they introduce significant delays. Urgent care suffers from this trade-off. Patient outcomes can worsen.
Rhovica's SoNav system directly tackles this challenge. It integrates advanced sensors. These provide real-time visualization. Guided catheter insertion occurs directly at the patient's bedside. SoNav eliminates the speed versus accuracy compromise. It ensures both swiftness and precision. This medical device marks a significant leap forward.
Beyond initial placement, SoNav offers continuous monitoring. It tracks brain ventricles. This feature reduces the need for repeated CT scans. Fewer scans mean less radiation exposure. Patient safety improves immediately. Outcomes are enhanced. Healthcare costs also see a notable reduction. The technology streamlines care pathways.
The €2.5 million financing round saw strong investor participation. M2care led the round. Swiss investment firms Kickfund and Valuemaker also joined. Several business angels contributed. These investors bring vital MedTech expertise and extensive networks. Their support is crucial for Rhovica's next development phase.
M2care is a European venture studio. Mérieux Développement and CEA Investissement created it. M2care specializes in healthtech. Its strategy involves combining investment capacity with hands-on expertise. This approach de-risks early-stage healthtech ventures. It prepares them for Series A readiness. M2care recognized Rhovica's strong potential.
Rhovica embodies M2care's investment philosophy. The startup addresses a clear clinical need. Its team is robust. The technology holds transformative power for emergency neurosurgery. M2care expressed pride in actively supporting Rhovica's journey. Their involvement is a strategic endorsement.
The neurosurgical device market shows significant growth potential. Rhovica positions itself strategically within this expanding environment. Industry projections indicate substantial expansion. Growth rates are expected between 4.5% and 14.2% in the coming years. SoNav is poised to capture a key segment.
Rhovica further strengthened its leadership. Carsten Laue joined its Board of Directors. Laue serves as Managing Director at M2care. His expertise is invaluable. He specializes in MedTech strategy and company building. Laue's guidance will accelerate SoNav's clinical adoption. His appointment signals a commitment to rapid progress.
Laue's decision to join the board reflects deep confidence. He aims to actively support Rhovica. His focus is translating a critical clinical need into a viable MedTech solution. SoNav's origin in emergency neurosurgical care is a key factor. The founders' complementary expertise further strengthens the project. This aligns perfectly with M2care's acceleration model.
The company's approach addresses a critical gap. Speed in emergency neurosurgery is paramount. Accuracy is non-negotiable. SoNav delivers both. It offers a new standard of care. Patients facing life-threatening brain conditions stand to benefit profoundly. This innovation can save lives and improve recovery.
Rhovica's success is a testament to focused innovation. The company identified a glaring problem. It engineered a sophisticated, yet practical, solution. The financial backing validates its vision. The strategic appointments strengthen its execution. SoNav promises a brighter future for emergency brain care globally.
The system's real-time capabilities are revolutionary. Surgeons gain unprecedented control. Procedural precision increases. Clinical outcomes improve significantly. The reduction in follow-up imaging lessens patient burden. It also optimizes hospital resources. Rhovica is not just developing a device; it is shaping a new paradigm for urgent medical intervention.